サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：散瞳治療の世界市場-2023年～2030年
市場調査レポート
商品コード
1374828

散瞳治療の世界市場-2023年～2030年

Global Mydriasis Treatment Market - 2023-2030

出版日
ページ情報
英文 187 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
散瞳治療の世界市場-2023年～2030年
出版日: 2023年11月01日
発行: DataM Intelligence
ページ情報: 英文 187 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

概要

散瞳は瞳孔散大とも呼ばれます。瞳孔散大は、目の中央の黒い部分が通常より大きくなることで起こります。この症状は、眼科検査で点眼された拡張剤、薬物や薬剤の副作用、外傷などによって引き起こされることがあります。瞳孔は光の変化や感情的な出来事によって自然に拡張しますが、異常な瞳孔の拡張は医学的な疾患の結果である可能性もあります。瞳孔の正常な大きさは、明るいところでは2～4ミリ、薄暗いところ（拡張した場合）では4～8ミリです。

また、ほとんどの場合、拡張した瞳孔は自然に元の大きさに戻ります。突然瞳孔が開いたり、外傷後に瞳孔が開いたり、頭痛や錯乱を起こしたりした場合は、すぐに医師の診察を受ける必要があります。散瞳の治療には、日光の感度を下げるためにサングラスを着用すること、特にフォトクロミックレンズや偏光レンズが一般的に使用されています。また、外傷によって瞳孔の大きさが変化した結果、目の見た目を改善するために人工コンタクトレンズを着用すること、薬物乱用のリハビリテーション、状況によっては怪我による目の損傷を修復するために手術を検討することもあります。

市場力学：促進要因

眼科ソリューションの採用増加

眼科用ソリューションの採用が増加していることが、予測期間中の市場を牽引するとみられます。点眼薬などの眼科用溶液は、非侵襲的な性質から散瞳患者に好まれることが多いです。この嗜好性により、処方された治療に対する患者のコンプライアンスが向上し、より良い治療結果につながります。採用が増加しているため、多くの企業が眼科用ソリューションの開発に注力しています。

例えば、2023年9月27日、Viatris Inc.は、米国食品医薬品局（FDA）がアドレナリン作動薬（例えば、フェニレフリン）または副交感神経溶解薬（例えば、トロピカミド）によって生じる薬理学的に誘発される散瞳の治療薬としてライズムビ（フェントラミン点眼液）0.75％を承認したと発表しました。

さらに、散瞳治療においてより良い結果を示す新しい点眼液の開発のために、多くの臨床試験が行われています。定期的な眼科検診と眼疾患の早期介入の重要性に関する国民の意識向上キャンペーンや教育イニシアティブは、眼科医療に対するより積極的なアプローチに貢献しています。このことが、主に散瞳治療における点眼液の採用を後押ししています。

さらに、新しい点眼薬に対するFDAの承認など、多くの規制当局の承認が、点眼薬の使用に対する患者の信頼を高めています。例えば、2023年2月13日、Ocuphire Pharma, Inc.は、薬理学的に誘発される散瞳の治療を目的としたNyxol（フェントラミン点眼液0.75%）の新薬承認申請（NDA）を米国食品医薬品局（FDA）から承認されました。

さらに、散瞳の有病率の増加、新規治療薬に対する規制当局の承認の増加、臨床試験および研究活動の増加、散瞳、散瞳レンズおよびその治療法に関する認知度の向上、新規治療法の開発における技術進歩が、予測期間にわたって市場を牽引すると予想されます。

阻害要因

手術に伴う合併症、点眼に伴う副作用、コンタクトレンズの不快感、散瞳治療にかかる高額な費用、より良い迅速な治療法の欠如などの要因が、市場の妨げになると予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 眼科ソリューションの採用拡大
    • 抑制要因
      • 手術に伴う合併症
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • パイプライン分析
  • アンメットニーズ
  • 特許分析
  • DMIのオピニオン

第6章 COVID-19分析

第7章 治療タイプ別

  • サングラス
    • フォトクロミックレンズ
    • 偏光レンズ
    • その他
  • 人工コンタクトレンズ
  • 手術
  • 薬物乱用リハビリ
  • 点眼薬
    • アトロピン
    • マイドリレート
    • ホマトロピン
    • フェニレフリン
    • その他
  • その他

第8章 販売チャネル別

  • 流通チャネル
    • 病院薬局
    • 小売薬局
    • オンライン薬局
  • エンドユーザー
    • 病院
    • 眼科クリニック
    • リハビリセンター
    • 外来手術センター
    • 学術研究機関
    • その他

第9章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第10章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第11章 企業プロファイル

  • Omeros Corporation
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Thea Laboratories
  • Ocuphire Pharma, Inc.
  • Alcon Inc.
  • Hoya Vision
  • Maui Jim USA, Inc.
  • Safilo Group S.p.A.
  • Global Calcium Pvt Ltd
  • VISION EASE
  • ZEISS Group

第12章 付録

目次
Product Code: PH7347

Overview

Mydriasis is also known as dilated pupils. Mydriasis occurs when the black center of the eyes is larger than normal. The condition may be caused by dilating eye drops from an eye exam, the side effects from any drugs or medication or traumatic injury. Pupils naturally dilate due to changes in light and emotional events, but unusual pupil dilation could be the result of a medical condition. A pupil's normal size is 2 to 4 millimeters in bright light and 4 to 8 millimeters in dim light (dilated).

Moreover, most of the time, dilated pupils will back to normal size on their own. If pupils dilate suddenly, occur after a traumatic injury or cause headaches and confusion, need to seek medical attention immediately. The treatment of mydriasis includes wearing sunglasses to reduce sunlight sensitivity, especially photochromic lenses and polarized lenses are commonly used, wearing prosthetic contact lenses to improve the appearance of eyes as the result of varying pupil size caused by trauma, substance abuse rehabilitation and in some situations surgery is considered to repair eye damage from injury.

Market Dynamics: Drivers

Increasing adoption of ophthalmic solutions

The increasing adoption of ophthalmic solutions is expected to drive the market over the forecast period. Ophthalmic solutions, such as eye drops are often mostly preferred by mydriasis patients due to their non-invasive nature. This preference increases patient compliance with the prescribed treatments, leading to better outcomes. Due to the increasing adoption, many companies are focussing on developing ophthalmic solutions.

For instance, on September 27, 2023, Viatris Inc. released that the U.S. Food and Drug Administration (FDA) approved RYZUMVI (phentolamine ophthalmic solution) 0.75% for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents.

Moreover, many clinical trials are going on for the development of novel ophthalmic solutions that show better results in mydriasis treatment. Public awareness campaigns and educational initiatives about the importance of regular eye examinations and early intervention for eye conditions are contributing to a more proactive approach to eye care. This, in turn, drives the adoption of ophthalmic solutions mostly in the treatment of mydriasis.

Further, many regulatory approvals such as FDA approvals for novel ophthalmic solutions increase the trust in patients for the usage of ophthalmic solutions. For instance, on February 13, 2023, Ocuphire Pharma, Inc. cleared the U.S. Food and Drug Administration (FDA) acceptance for the New Drug Application (NDA) for Nyxol (phentolamine ophthalmic solution 0.75%) for the treatment of pharmacologically-induced mydriasis.

Further, the increasing prevalence of mydriasis, rising regulatory approvals for novel therapeutics, increasing clinical trials and research activities, increasing awareness about mydriasis, mydriatic lenses and their treatment and technological advancements in developing novel treatments are expected to drive the market over the forecast period.

Restraints

Factors such as complications associated with the surgery, side effects associated with the eye drops, the discomfort of the contact lenses, the high cost of the treatment of mydriasis and lack of better and quick treatment are expected to hamper the market.

Segment Analysis

The global mydriasis treatment market is segmented based on treatment type, sales channel and region.

The sunglasses segment accounted for approximately 42.2% of the mydriasis treatment market share

The sunglasses segment is expected to hold the largest market share over the forecast period. Sunglasses with photochromic lenses and polarized lenses are most commonly used to reduce sunlight sensitivity. Sometimes, individuals with mydriasis experience increased sensitivity to light, in such situations, sunglasses can help manage this sensitivity of the light by reducing the amount of light entering the eyes.

In addition, after certain eye surgeries or other mydriatic medical procedures, patients may be advised to wear sunglasses to protect the eyes from bright light and it reduces discomfort. While mydriatic sunglasses do not directly treat mydriasis, they can provide symptomatic relief by minimizing discomfort caused by bright light, glare, or intense sunlight.

Further, the wide availability and acceptability of the mydriatic sunglasses helps to hold the largest market share. In addition, their wide adoption also increases the demand for the sunglasses.

Geographical Analysis

North America accounted for approximately 39.2% of the market share

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and increasing research activities. North America especially the United States is known for its strong presence of major players such as pharmaceutical companies and medical device companies for developing novel ophthalmic solutions and advanced eyewear such as sunglasses and contact lenses. The presence of major players actively performing in clinical trials, leads to the launch of novel therapeutics and alternative treatment options for the treatment of mydriasis.

Furthermore, the increasing research activities especially in the United States also helps to develop more advanced therapeutics for the better management of the symptoms in the early stages. As the research activities increase, the therapeutics are developed more precisely by reducing the adverse effects and complications associated with the therapeutics and devices, which results in better patient outcomes.

Competitive Landscape

The major global players in the mydriasis treatment market include: Omeros Corporation, Thea Laboratories, Ocuphire Pharma, Inc., Alcon Inc., Hoya Vision, Maui Jim USA, Inc., Safilo Group S.p.A., Global Calcium Pvt Ltd, VISION EASE, ZEISS Group and among others.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global mydriasis treatment market. The pandemic created unprecedented challenges for pharmaceutical industries worldwide. During the pandemic, many clinical trials, research activities and regulatory approvals are temporarily disrupted or postponed due to the redirected focus on the COVID-19 pandemic and its related restrictions. The pandemic also disrupted the supply chain of these treatment medications and eyewear globally.

Market Segmentation

By Treatment Type

  • Sunglasses
    • Photochromic Lenses
    • Polarized Lenses
    • Others
  • Prosthetic Contact Lenses
  • Surgery
  • Substance Abuse Rehabilitation
  • Eye Drops
    • Atropine
    • Mydrilate
    • Homatropine
    • Phenylephrine
    • Others
  • Others

By Sales Channel

  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • End-User
    • Hospitals
    • Ophthalmic Clinics
    • Rehabilitation Centers
    • Ambulatory Surgical Centers
    • Academic and Research Institutes
    • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Why Purchase the Report?

  • To visualize the global mydriasis treatment market segmentation based on treatment type, sales channel and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development
  • Excel data sheet with numerous data points of mydriasis treatment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global mydriasis treatment market report would provide approximately 53 tables, 49 figures, and 187 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Treatment Type
  • 3.2. Snippet by Sales Channel
  • 3.3. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Adoption of Ophthalmic Solutions
    • 4.1.2. Restraints
      • 4.1.2.1. Complications Associated with the Surgery
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Pipeline Analysis
  • 5.6. Unmet Needs
  • 5.7. Patent Analysis
  • 5.8. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Treatment Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 7.1.2. Market Attractiveness Index, By Treatment Type
  • 7.2. Sunglasses*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.3. Photochromic Lenses
    • 7.2.4. Polarized Lenses
    • 7.2.5. Others
  • 7.3. Prosthetic Contact Lenses
  • 7.4. Surgery
  • 7.5. Substance Abuse Rehabilitation
  • 7.6. Eye Drops
    • 7.6.1. Atropine
    • 7.6.2. Mydrilate
    • 7.6.3. Homatropine
    • 7.6.4. Phenylephrine
    • 7.6.5. Others
  • 7.7. Others

8. By Sales Channel

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 8.1.2. Market Attractiveness Index, By Sales Channel
  • 8.2. Distribution Channel*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 8.2.3. Hospital Pharmacies
    • 8.2.4. Retail Pharmacies
    • 8.2.5. Online Pharmacies
  • 8.3. End-User
    • 8.3.1. Hospitals
    • 8.3.2. Ophthalmic Clinics
    • 8.3.3. Rehabilitation Centers
    • 8.3.4. Ambulatory Surgical Centers
    • 8.3.5. Academic and Research Institutes
    • 8.3.6. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. UK
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Omeros Corporation*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. Thea Laboratories
  • 11.3. Ocuphire Pharma, Inc.
  • 11.4. Alcon Inc.
  • 11.5. Hoya Vision
  • 11.6. Maui Jim USA, Inc.
  • 11.7. Safilo Group S.p.A.
  • 11.8. Global Calcium Pvt Ltd
  • 11.9. VISION EASE
  • 11.10. ZEISS Group

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us